News headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have trended positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.1457081834185 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Separately, ValuEngine raised shares of Cyclacel Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) remained flat at $$1.60 during mid-day trading on Monday. The stock had a trading volume of 31,600 shares, compared to its average volume of 259,364. Cyclacel Pharmaceuticals has a 12-month low of $1.47 and a 12-month high of $10.90. The firm has a market capitalization of $19.05, a P/E ratio of -0.65 and a beta of 3.75.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.